FDA Calls for Sweeping Review of Opioids Policies

FDA Calls for Sweeping Review of Opioids Policies

Top officials for the organization have called for an action plan to reassess the agency's approach to opioid medications. FDA also will convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties.

Dr. Robert Califf, deputy commissioner for Medical Products and Tobacco for the FDA, and other top agency officials have called for an action plan to reassess the agency's approach to opioid medications. The plan will focus on policies aimed at reversing the epidemic while still providing patients access to effective relief.

FDA will also seek outside guidance from experts in pain management and drug abuse.

"We are determined to help defeat this epidemic through a science-based and continuously evolving approach," said Califf. "This plan contains real measures this agency can take to make a difference in the lives of so many people who are struggling under the weight of this terrible crisis."

The agency also is making the requirements for drug companies to generate postmarket data stronger, resulting in more comprehensive data with regards to pain medicine and treatments for opioid use disorder.

"Agencies from across the Department of Health and Human Services and throughout the federal government are united in aggressively addressing this public health crisis," said U.S. Health and Human Services Secretary Sylvia M. Burwell. "The FDA is a vital component to combating this epidemic, and the innovation and modernization they have committed to undertaking is an important part of the overall efforts at HHS."

FDA indicated it will re-examine the risk-benefit paradigm for opioids and ensure that the agency considers their wider public health effects and also will convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties.

FDA reported it already has asked the National Academies of Sciences, Engineering, and Medicine to help develop a framework for opioid review, approval, and monitoring, a framework that balances individuals' need for pain control with considerations of the broader public health consequences of opioid misuse and abuse.

Product Showcase

  • The MGC Simple Plus

    The MGC Simple Plus

    The MGC Simple Plus is a simple-to-use, portable multi-gas detector that runs continuously for three years without needing to be recharged or routinely calibrated after its initial charge and calibration during manufacturing. The detector reliably tests a worksite’s atmosphere for hydrogen sulfide, carbon monoxide, oxygen and combustible gases (LEL). Additionally, it is durable enough to withstand the harshest treatment and environments, which is why it has an IP 68 rating. The MGC Simple Plus is also compatible with a variety of accessories, such as Gas Clip Technologies’ new GCT External Pump. Visit gascliptech.com for more information. 3

  • Magellan X Pte Ltd

    Hesitate No More with SOL-X Connected Worker Health & Safety Solution

    According to the National Safety Council, work-related medically consulted injuries total 4.26 million in 2021 in USA alone. SOL-X solution prevents “human factors” safety issues by anticipating incidents and improving compliance workflows. Leverages digital technologies (IIoT, AI and analytics) to predict patterns from occurring and make informed decisions. Control Of Work - gets rid of tedious paperwork and experience digital workflows. Crew Protect - maximises safety and situational awareness with health trackers and situational indicators. Award-winning Intrinsically Safe SmartWatch – innovative features that enable near real-time visibility and connected well-being. Works well with major connectivity protocols like Wi-Fi, Bluetooth, and Long-Range Bluetooth! 3

Featured